Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer

James R. Rigas, Primo N Lara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The treatment of unresectable stage III NSCLC remains challenging. However, in the last two decades, advances in terms of survival prolongation have been made, first by administering chemotherapy with definitive thoracic radiotherapy sequentially, and then by administering these two modalities concurrently. Most recently, induction and consolidation regimens have been evaluated which involve adding chemotherapy before concurrent chemoradiotherapy (as induction) or after (as consolidation). Thus far, the consolidation approach appears to be promising. For example, concurrent chemoradiotherapy with cisplatin and etoposide followed by consolidation docetaxel yielded an impressive median survival of 26 months in a Southwest Oncology Group phase II trial. A phase III trial showed interesting results in a subset of patients that received docetaxel consolidation prior to randomization to gefitinib or placebo. Although stopped early due to lack of benefit of gefitinib, preliminary results showed a median survival time of 29 months in the placebo arm. A randomized trial is currently underway that compares concurrent chemoradiotherapy (using cisplatin and etoposide) followed by either docetaxel consolidation or no further therapy.

Original languageEnglish (US)
JournalLung Cancer
Volume50
Issue numberSUPPL. 2
DOIs
StatePublished - Dec 2005

Fingerprint

docetaxel
Chemoradiotherapy
Non-Small Cell Lung Carcinoma
Etoposide
Cisplatin
Survival
Placebos
Drug Therapy
Random Allocation
Radiotherapy
Thorax
Therapeutics

Keywords

  • Chemotherapy
  • Cisplatin
  • Consolidation
  • Docetaxel
  • Etoposide
  • Non-small cell lung cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer. / Rigas, James R.; Lara, Primo N.

In: Lung Cancer, Vol. 50, No. SUPPL. 2, 12.2005.

Research output: Contribution to journalArticle

@article{a2e943fdf1724e7398f7f4ad7dc23500,
title = "Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer",
abstract = "The treatment of unresectable stage III NSCLC remains challenging. However, in the last two decades, advances in terms of survival prolongation have been made, first by administering chemotherapy with definitive thoracic radiotherapy sequentially, and then by administering these two modalities concurrently. Most recently, induction and consolidation regimens have been evaluated which involve adding chemotherapy before concurrent chemoradiotherapy (as induction) or after (as consolidation). Thus far, the consolidation approach appears to be promising. For example, concurrent chemoradiotherapy with cisplatin and etoposide followed by consolidation docetaxel yielded an impressive median survival of 26 months in a Southwest Oncology Group phase II trial. A phase III trial showed interesting results in a subset of patients that received docetaxel consolidation prior to randomization to gefitinib or placebo. Although stopped early due to lack of benefit of gefitinib, preliminary results showed a median survival time of 29 months in the placebo arm. A randomized trial is currently underway that compares concurrent chemoradiotherapy (using cisplatin and etoposide) followed by either docetaxel consolidation or no further therapy.",
keywords = "Chemotherapy, Cisplatin, Consolidation, Docetaxel, Etoposide, Non-small cell lung cancer, Radiotherapy",
author = "Rigas, {James R.} and Lara, {Primo N}",
year = "2005",
month = "12",
doi = "10.1016/S0169-5002(05)81569-7",
language = "English (US)",
volume = "50",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Current perspectives on treatment strategies for locally advanced, unresectable stage III non-small cell lung cancer

AU - Rigas, James R.

AU - Lara, Primo N

PY - 2005/12

Y1 - 2005/12

N2 - The treatment of unresectable stage III NSCLC remains challenging. However, in the last two decades, advances in terms of survival prolongation have been made, first by administering chemotherapy with definitive thoracic radiotherapy sequentially, and then by administering these two modalities concurrently. Most recently, induction and consolidation regimens have been evaluated which involve adding chemotherapy before concurrent chemoradiotherapy (as induction) or after (as consolidation). Thus far, the consolidation approach appears to be promising. For example, concurrent chemoradiotherapy with cisplatin and etoposide followed by consolidation docetaxel yielded an impressive median survival of 26 months in a Southwest Oncology Group phase II trial. A phase III trial showed interesting results in a subset of patients that received docetaxel consolidation prior to randomization to gefitinib or placebo. Although stopped early due to lack of benefit of gefitinib, preliminary results showed a median survival time of 29 months in the placebo arm. A randomized trial is currently underway that compares concurrent chemoradiotherapy (using cisplatin and etoposide) followed by either docetaxel consolidation or no further therapy.

AB - The treatment of unresectable stage III NSCLC remains challenging. However, in the last two decades, advances in terms of survival prolongation have been made, first by administering chemotherapy with definitive thoracic radiotherapy sequentially, and then by administering these two modalities concurrently. Most recently, induction and consolidation regimens have been evaluated which involve adding chemotherapy before concurrent chemoradiotherapy (as induction) or after (as consolidation). Thus far, the consolidation approach appears to be promising. For example, concurrent chemoradiotherapy with cisplatin and etoposide followed by consolidation docetaxel yielded an impressive median survival of 26 months in a Southwest Oncology Group phase II trial. A phase III trial showed interesting results in a subset of patients that received docetaxel consolidation prior to randomization to gefitinib or placebo. Although stopped early due to lack of benefit of gefitinib, preliminary results showed a median survival time of 29 months in the placebo arm. A randomized trial is currently underway that compares concurrent chemoradiotherapy (using cisplatin and etoposide) followed by either docetaxel consolidation or no further therapy.

KW - Chemotherapy

KW - Cisplatin

KW - Consolidation

KW - Docetaxel

KW - Etoposide

KW - Non-small cell lung cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=33645025157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645025157&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(05)81569-7

DO - 10.1016/S0169-5002(05)81569-7

M3 - Article

C2 - 16557670

AN - SCOPUS:33645025157

VL - 50

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - SUPPL. 2

ER -